Nektar Therapeutics ã¯ãã€ãªå»è¬åäŒç€ŸãšããŠéå¶ãããŠããŸããå瀟ã¯ãè
«çåŠãå
ç«åŠããŠã€ã«ã¹åŠã®æ²»éšè¬ã®ãã€ãã©ã€ã³ã®ã»ããæ¿èªæžã¿ã®ææºå»è¬åã®ããŒããã©ãªãªãç ç©¶éçºããŠããŸããå瀟ã®è£œåã«ã¯ã転移æ§é»è²è
«ãè
现èçãç局浞最æ§èè±çãããã³è£å©é»è²è
«ã®æ²»çãç®çãšãã第 3 çžèšåºè©Šéšäžã® CD122 åªå
ã€ã³ã¿ãŒãã€ãã³-2 (IL-2) çµè·¯ã¢ãŽãã¹ãã§ãã Bempegaldesleukinãè
现èçããã³å°¿è·¯äžç®çã®æ²»çãç®çãšãã第 2 çžèšåºè©Šéšãé é žéšæå¹³äžç®çã®æ²»çãç®çãšãã第 1/2A çžèšåºè©Šéšãéå°çްèèºçããã³å
ç«è
«çåŠã®æ²»çãç®çãšãã第 1/2 çžèšåºè©Šéšãªã©ããããŸããå瀟ã¯ãŸããCOVID-19ã®æ²»çè¬ãšããŠç¬¬2çžèšåºè©Šéšãšã¢ãããŒæ§ç®èçãšä¹Ÿç¬ã®æ²»çè¬ãšããŠç¬¬1Bçžèšåºè©Šéšãé²è¡äžã®ãµã€ãã«ã€ã³Tregåºæ¿è¬NKTR-358ãéããžãã³ãªã³ãè
«ãšå€çºæ§éªšé«è
«ãé é žéšãããšå€§è
žããã®æ²»çè¬ãšããŠç¬¬2çžèšåºè©Šéšãé²è¡äžã®IL-15å容äœäœåè¬NKTR-255ã屿é²è¡æ§ãŸãã¯è»¢ç§»æ§åºåœ¢è
«çã®æ²»çè¬ãšããŠç¬¬1/2çžèšåºè©Šéšãé²è¡äžã®Tollæ§å容äœäœåè¬NKTR-262ããã®ä»ããŸããŸãªåè£è¬ãéçºããŠãããåç€Ÿã¯æŠç°è¬åå·¥æ¥ãã¢ã¹ãã©ãŒãã«ãUCBãã¡ãŒããF.ãããã³ã»ã©ã»ãã·ã¥ãããŠã·ã¥ã»ãã«ã¹ã»ã«ã³ãããŒãºããã¡ã€ã¶ãŒç€Ÿãã¢ã ãžã§ã³ç€ŸãUCBãã¡ãŒãïŒãã€ãªãžã§ã³ïŒãããªã¹ãã«ã»ãã€ã€ãŒãºã¹ã¯ã€ã瀟ããã¯ã¹ã¢ã«ã¿ç€Ÿãã€ãŒã©ã€ãªãªãŒç€Ÿãã¡ã«ã¯ç€ŸãSFJãã¡ãŒãã·ã¥ãŒãã£ã«ã«ãºç€Ÿããã¯ã¿ãŒã»ã»ã©ãã¥ãŒãã£ã¯ã¹ã¯1990幎ã«èšç«ãããã«ãªãã©ã«ãã¢å·ãµã³ãã©ã³ã·ã¹ã³ã«æ¬ç€Ÿã眮ããã¢ã©ããå·ãã³ããã«ãšã€ã³ãã®ãã€ãã©ããŒãã«ãäºæ¥æãæ§ããŠããŸãã